Sign in
Not yet recruitingNo phase

Early blood sugar testing for gestational diabetes in pregnant women at low risk

Tests early glucose screening for gestational diabetes in pregnant women considered low risk.

Key facts

Who runs it
National University Hospital, Singapore
Where
Singapore1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Early Screening for Gestational Diabetes Mellitus in a Low Risk Population
Status
Not yet recruiting
People taking part
120 people, planned
Started
1 Dec 2024
Expected to end
30 Nov 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Early OGTT Results Revealed
Record updated
25 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women at low risk of diabetes in pregnancy, less than 16 weeks pregnant. It tests an early sugar tolerance test (OGTT).

Age
21 to 39 years
Sex
Women only
Disease stage
Pregnant with one baby, less than 16 weeks pregnant, low risk of gestational diabetes. Must plan pregnancy care and birth at the National University Hospital.
Earlier treatment
People taking steroid medicine for the whole body or metformin cannot join.

Main reasons for not taking part

  • Known type 1 or type 2 diabetes
  • High risk of gestational diabetes, such as BMI ≥25.0 kg/m2, a parent, sibling or child with diabetes, or gestational diabetes before
  • Earlier baby weighing ≥4 kg (9 lb), polycystic ovarian syndrome, or a poor pregnancy history
  • Long-term high blood pressure, high blood fats, heart disease, or sugar in urine ≥ 2+
  • Taking part in another intervention trial

This trial only enrols pregnant participants. The registry sentence this rests on: 1. Pregnant women aged 21-39 years at recruitment

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Pregnant women aged 21-39 years at recruitment
  • Singleton pregnancy
  • Less than 16 weeks pregnant at recruitment
  • Intend to receive antenatal care and give birth at the National University Hospital

Who cannot take part

  • Taking systemic steroid medication or metformin
  • Known pre-existing type 1 or type 2 diabetes mellitus at recruitment
  • Classified as high-risk for GDM at pregnancy booking using the traditional checklist:; 2.1) Age ≥40 years 2.2) Overweight/obese, i.e., body mass index (BMI) ≥25.0 kg/m2 2.3) First degree relative with diabetes mellitus 2.4) Previously delivered a baby ≥4 kg 2.5) Previously diagnosed with GDM 2.6) Impaired glucose tolerance (IGT) or impaired fasting glycaemia (IFG) on previous testing 2.7) Polycystic ovarian syndrome (PCOS) 2.8) Poor obstetric history (e.g. recurrent pregnancy loss, previous intrauterine death, congenital malformations) 2.9) History of chronic hypertension, hyperlipidaemia or cardiovascular disease 2.10) Glycosuria ≥ 2+ on urine dipstick
  • Participation in another intervention trial

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 39 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This new feasibility pilot study aims to refine the design and protocols for a larger trial that will investigate the potential benefits of early oral glucose tolerance test (OGTT) screening in a population traditionally defined as low-risk for development of gestational diabetes. The study will evaluate its potential effectiveness in reducing the risks of neonatal morbidity/mortality and obstetric complications. Additionally, a machine learning algorithm to predict gestational diabetes mellitus (GDM) risk based on routinely obtained clinical information at pregnancy booking, and minimally invasive methods, such as continuous glucose monitoring (CGM) and gingival crevicular fluid (GCF) sampling, are being explored to predict the risk of hyperglycaemia. This study aims to investigate the utility of early pregnancy screening to enable timely detection and management of early gestational diabetes development in a low-risk population, ultimately promoting better health outcomes for mothers and their babies.

The 2 groups in the trial

  • Early OGTT Results RevealedTreatment being tested

    The results of the early OGTT conducted before 16 weeks' gestation will be revealed to the participants. If the results indicate gestational diabetes mellitus (GDM) by the WHO 2013 criteria, immediate follow-up actions, including appropriate treatments, will be taken. Those with a normal result will undertake the universally offered routine OGTT at 24-28 weeks' gestation.

  • Early OGTT Results ConcealedNo study treatment, for comparison

    Participants in this arm will undergo an early oral glucose tolerance test (OGTT) before 16 weeks' gestation, however, the results will be concealed from the participants and study investigators, and results will not be acted upon (unless they are suggestive of pre-existing type 2 diabetes mellitus as reviewed by an independent clinician, in which case appropriate follow-up will be arranged). All participants (except those with results suggestive of type 2 diabetes) will undertake the routine OGTT at 24-28 weeks' gestation, as per standard care.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Early Screening for Gestational Diabetes Mellitus in a Low Risk Population
Plain-language title
Early blood sugar testing for gestational diabetes in pregnant women at low riskGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT06704035, who can take part
Record updated
25 November 2024